nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-191-7-81-89nogr-1704Research ArticleОБЗОРREVIEWГоризонты развития иммунотерапии злокачественных новообразований печениHorizons of development of immunotherapy for malignant liver tumorshttps://orcid.org/0000-0001-8973-7890МухинВ. Е.MukhinV. E.vmukhin@cspmz.ruhttps://orcid.org/0000-0002-0422-2060КонстантиноваЮ. С.KonstantinovaYu. S.noemail@neicon.ruhttps://orcid.org/0000-0002-9567-3317ГимадиевР. Р.GimadievR. R.noemail@neicon.ruhttps://orcid.org/0000-0002-2524-9203МазурчикН. В.MazurchikN. V.noemail@neicon.ruФГБУ «ЦСП» ФМБА РоссииРоссияFederal State Budgetary Institution “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Federal Medical Biological AgencyRussian FederationФГАОУ ВО «Российский университет дружбы народов»РоссияFederal State Autonomous Educational Institution for Higher Education “Peoples’ Friendship University of Russia”Russian Federation202127092021078189Copyright © Мухин В.Е., Константинова Ю.С., Гимадиев Р.Р., Мазурчик Н.В., 20212021Мухин В.Е., Константинова Ю.С., Гимадиев Р.Р., Мазурчик Н.В.Mukhin V.E., Konstantinova Y.S., Gimadiev R.R., Mazurchik N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1704

Первичные опухоли печени являются одним из наиболее распространенных типов злокачественных новообразований. Хирургическая резекция по-прежнему остается наиболее эффективным методом лечения на ранних стадиях заболевания, однако в большинстве случаев ранняя диагностика затруднена. Кроме того, даже если лечение проведено по радикальной программе, риск рецидива остается крайне высоким. В связи с этим не прекращается поиск новых стратегий терапии злокачественных новообразований печени, отличных от традиционных методов лечения. Одним из таких перспективных подходов является иммунотерапия. Данный обзор посвящен современным представлениям о механизмах действия и имеющимся клиническом опыте применения иммунотерапевтических подходов в лечении злокачественных новообразований печени. Комбинирование различных видов иммунотерапии или сочетание иммунотерапии с традиционными терапевтическими подходами может обеспечить синергетический эффект и способствовать развитию персонализированной медицины.

Primary liver tumors are one of the most common types of malignant neoplasms. Surgical excision is still the most effective treatment in the early stages of the disease, however in most cases early diagnosis is difficult. Moreover, even if the treatment is carried out according to a radical program, the risk of relapse remains extremely high. In this regard, the search for new strategies for the treatment of liver malignancies that differ from traditional methods of treatment is not terminated. One of such promising approaches is immunotherapy. The present review is devoted to the current understanding of the mechanisms of action and the available clinical experience in the use of immunotherapy approaches in the treatment of liver malignancies. Combining different types of immunotherapy or combining immunotherapy with traditional therapeutic approaches can facilitate a synergistic effect and contribute to the development of personalized medicine.

Иммунотерапиягепатоцеллюлярная карциномазлокачественные новообразования печениопухолевое микроокружениеImmunotherapyhepatocellular carcinomaliver cancertumor microenvironmentReferencesChekmazov IA, Ivanikov IO, Sapronov GV, Kirillova NCh, Vinogradova NN. Liver cancer: etiology, pathogenesis, results of long-term clinical and epidemiological observation (in Russian only). Russian journal of Evidence-based gastroenterology = Dokazatel’naya gastroenterologiya. 2019;8(1):5-15. (In Russ.) Doi: 10.17116/dokgastro201980115@@ Чекмазов И. А., Иваников И. О., Сапронов Г. В., Кириллова Н. Ч., Виноградова Н. Н. Рак печени: этиология, патогенез, итоги длительного клинико-эпидемиологического наблюдения. Доказательная гастроэнтерология. 2019;8(1):5-15.Chekmazov IA, Ivanikov IO, Sapronov GV, Kirillova NCh, Vinogradova NN. Liver cancer: etiology, pathogenesis, results of long-term clinical and epidemiological observation (in Russian only). Russian journal of Evidence-based gastroenterology = Dokazatel’naya gastroenterologiya. 2019;8(1):5-15. (In Russ.) Doi: 10.17116/dokgastro201980115@@ Чекмазов И. А., Иваников И. О., Сапронов Г. В., Кириллова Н. Ч., Виноградова Н. Н. Рак печени: этиология, патогенез, итоги длительного клинико-эпидемиологического наблюдения. Доказательная гастроэнтерология. 2019;8(1):5-15.Shchegolev AI, Tumanova UN, Mishnev OD. Risk factors of hepatocellular carcinoma. International journal of applied and fundamental research. 2018; 9:164-169. (In Russ.)@@ Щеголев А. И., Туманова У. Н., Мишнёв О. Д. Факторы риска развития гепатоцеллюлярной карциномы. Международный журнал прикладных и фундаментальных исследований. 2018;9:164-169.Shchegolev AI, Tumanova UN, Mishnev OD. Risk factors of hepatocellular carcinoma. International journal of applied and fundamental research. 2018; 9:164-169. (In Russ.)@@ Щеголев А. И., Туманова У. Н., Мишнёв О. Д. Факторы риска развития гепатоцеллюлярной карциномы. Международный журнал прикладных и фундаментальных исследований. 2018;9:164-169.Ozakyol A. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). J Gastrointest Canc. 2017; 48:238-240. Doi: 10.1007/s12029-017-9959-0.Ozakyol A. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). J Gastrointest Canc. 2017; 48:238-240. Doi: 10.1007/s12029-017-9959-0.Merabishvili V.M., Chepik O.f., Merabishvili E. N. Dynamics of observed and relative survival of patients with primary liver cancer on the population level according to disease stage and histological structure. Siberian journal of oncology. 2015;1(4):5-11. (In Russ.)@@ Мерабишвили В. М., Чепик О. Ф., & Мерабишвили Э. Н. Динамика наблюдаемой и относительной выживаемости больных первичным раком печени на популяционном уровне с учетом стадии заболевания и гистологической структуры. Сибирский онкологический журнал. 2015; (4), 5-11.Merabishvili V.M., Chepik O.f., Merabishvili E. N. Dynamics of observed and relative survival of patients with primary liver cancer on the population level according to disease stage and histological structure. Siberian journal of oncology. 2015;1(4):5-11. (In Russ.)@@ Мерабишвили В. М., Чепик О. Ф., & Мерабишвили Э. Н. Динамика наблюдаемой и относительной выживаемости больных первичным раком печени на популяционном уровне с учетом стадии заболевания и гистологической структуры. Сибирский онкологический журнал. 2015; (4), 5-11.Moini M., Schilsky M. L., Tichy E. M. Review on immunosuppression in liver transplantation. World journal of hepatology. 2015; 7(10):1355. Doi: 10.4254/wjh.v7.i10.1355Moini M., Schilsky M. L., Tichy E. M. Review on immunosuppression in liver transplantation. World journal of hepatology. 2015; 7(10):1355. Doi: 10.4254/wjh.v7.i10.1355Robinson M. W., Harmo, C., O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cellular & molecular immunology. 2016; 13(3):267-276. Doi: 10.1038/cmi.2016.3.Robinson M. W., Harmo, C., O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cellular & molecular immunology. 2016; 13(3):267-276. Doi: 10.1038/cmi.2016.3.Guha P., Reha J., Katz. S. C. Immunosuppression in liver tumors: opening the portal to effective immunotherapy. Cancer gene therapy. 2017; 24(3):114-120. Doi: 10.1038/ cgt.2016.54Guha P., Reha J., Katz. S. C. Immunosuppression in liver tumors: opening the portal to effective immunotherapy. Cancer gene therapy. 2017; 24(3):114-120. Doi: 10.1038/ cgt.2016.54Whiteside T. L. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther. 2014;14(10):1411-25. Doi: 10.1517/14712598.2014Whiteside T. L. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther. 2014;14(10):1411-25. Doi: 10.1517/14712598.2014Whiteside TL. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Ther Targets. 2018; 22(4):353-363. Doi: 10.1080/14728222.2018.1451514Whiteside TL. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Ther Targets. 2018; 22(4):353-363. Doi: 10.1080/14728222.2018.1451514Jinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N. et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology. 2007; 120: 73-82. Doi: 10.1111/j.1365-2567.2006.02479.xJinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N. et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology. 2007; 120: 73-82. Doi: 10.1111/j.1365-2567.2006.02479.xTyznik A.J., Verma S., Wang Q., Kronenberg M,. Benedict C. A. Distinct requirements for activation of NKT and NK cells during viral infection. J Immunol. 2014; 192:3676-3685. Doi: 10.4049/jimmunol.1300837Tyznik A.J., Verma S., Wang Q., Kronenberg M,. Benedict C. A. Distinct requirements for activation of NKT and NK cells during viral infection. J Immunol. 2014; 192:3676-3685. Doi: 10.4049/jimmunol.1300837Liu P., Chen L., Zhang H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. J Immunol Res. 2018; 2018:1206737. Doi: 10.1155/2018/1206737Liu P., Chen L., Zhang H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. J Immunol Res. 2018; 2018:1206737. Doi: 10.1155/2018/1206737Horst A.K., Neumann K., Diehl L., Tiegs G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol Immunol. 2016; 13: 277-292. Doi: 10.1038/cmi.2015.112.Horst A.K., Neumann K., Diehl L., Tiegs G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol Immunol. 2016; 13: 277-292. Doi: 10.1038/cmi.2015.112.Knolle P.A., Germann T., Treichel U., Uhrig A., Schmitt E., Hegenbarth S. et al. Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J Immunol. 1999; 162: 1401-1407.Knolle P.A., Germann T., Treichel U., Uhrig A., Schmitt E., Hegenbarth S. et al. Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J Immunol. 1999; 162: 1401-1407.Carambia A, Frenzel C, Bruns OT, Schwinge D, Reimer R, Hohenberg H et al. Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells. J Hepatol. 2013; 58: 112-118. Doi: 10.1016/j.jhep.2012.09.008Carambia A, Frenzel C, Bruns OT, Schwinge D, Reimer R, Hohenberg H et al. Inhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells. J Hepatol. 2013; 58: 112-118. Doi: 10.1016/j.jhep.2012.09.008Heymann F., Peusquens J., Ludwig-Portugall I., Kohlhepp M., Ergen C., Niemietz P. et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015; 62: 279-291. Doi: 10.1002/hep.27793Heymann F., Peusquens J., Ludwig-Portugall I., Kohlhepp M., Ergen C., Niemietz P. et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015; 62: 279-291. Doi: 10.1002/hep.27793Xie Z, Chen Y, Zhao S, Yang Z, Yao X, Guo S et al. Intrahepatic PD-1/PD-L1 upregulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest. 2009; 38: 624-638. Doi: 10.1080/08820130903062210.Xie Z, Chen Y, Zhao S, Yang Z, Yao X, Guo S et al. Intrahepatic PD-1/PD-L1 upregulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest. 2009; 38: 624-638. Doi: 10.1080/08820130903062210.Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA. 2008; 105: 10113-10118. Doi: 10.1073/pnas.0711106105.Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA. 2008; 105: 10113-10118. Doi: 10.1073/pnas.0711106105.Motta JM, Rumjanek VM. Sensitivity of Dendritic Cells to Microenvironment Signals. J Immunol Res. 2016; 2016:4753607. Doi: 10.1155/2016/4753607Motta JM, Rumjanek VM. Sensitivity of Dendritic Cells to Microenvironment Signals. J Immunol Res. 2016; 2016:4753607. Doi: 10.1155/2016/4753607Heusinkveld M., van der Burg S. H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 2011; 16 (9): 216. Doi: 10.1186/1479-5876-9-216Heusinkveld M., van der Burg S. H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 2011; 16 (9): 216. Doi: 10.1186/1479-5876-9-216Porta C., Riboldi E., Ippolito A., Sica A. Molecular and epigenetic basis of macrophage polarized activation. Semin. Immunol. 2015; 27 (4): 237-48. Doi: 10.1016/j.smim.2015.10.003.Porta C., Riboldi E., Ippolito A., Sica A. Molecular and epigenetic basis of macrophage polarized activation. Semin. Immunol. 2015; 27 (4): 237-48. Doi: 10.1016/j.smim.2015.10.003.Chamarthy M.R., Williams S. C., Moadel R. M. Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ‘magic bullets’ to ‘radioactive magic bullets’ Yale J. Biol. Med., 2011; 84 (4):391.Chamarthy M.R., Williams S. C., Moadel R. M. Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ‘magic bullets’ to ‘radioactive magic bullets’ Yale J. Biol. Med., 2011; 84 (4):391.Lovet J.M., Zucman-Rossi J., Pikarsky E., Sangro B., Schwartz M., Sherman M., et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. Doi: 10.1038/nrdpLovet J.M., Zucman-Rossi J., Pikarsky E., Sangro B., Schwartz M., Sherman M., et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. Doi: 10.1038/nrdpCouzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432-1433. Doi: 10.1126/science.342.6165.1432.Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432-1433. Doi: 10.1126/science.342.6165.1432.Spiers L., Coupe N., Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford). 2019;58(Suppl 7): vii7-vii16. Doi: 10.1093/rheumatology/kez418.Spiers L., Coupe N., Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford). 2019;58(Suppl 7): vii7-vii16. Doi: 10.1093/rheumatology/kez418.Scott A.M., Allison J. P., Wolchok J. D. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.Scott A.M., Allison J. P., Wolchok J. D. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.Nishida T., Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11(9):1339. https://doi.org/Nishida T., Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11(9):1339. https://doi.org/Ishiguro T., Sugimoto M., Kinoshita Y., Miyazaki Y., Nakano K., et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008; 68(23):9832-8. Doi: 10.3390/cancers11091339Ishiguro T., Sugimoto M., Kinoshita Y., Miyazaki Y., Nakano K., et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008; 68(23):9832-8. Doi: 10.3390/cancers11091339Abou-Alfa G.K., Puig O., Daniele B., Kudo M., Merle P. et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016; 65(2):289-95. Doi: 10.1016/j.jhep.2016.04.004Abou-Alfa G.K., Puig O., Daniele B., Kudo M., Merle P. et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016; 65(2):289-95. Doi: 10.1016/j.jhep.2016.04.004Ishiguro T., Sano Y., Komatsu S. I., Kamata-Sakurai M., Kaneko A., Kinoshita Y. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Science translational medicine. 2017. 9 p. Doi: 10.1126/scitranslmed.aal4291Ishiguro T., Sano Y., Komatsu S. I., Kamata-Sakurai M., Kaneko A., Kinoshita Y. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Science translational medicine. 2017. 9 p. Doi: 10.1126/scitranslmed.aal4291Assal A., Kaner J., Pendurti G., Zang X. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy. 2015;7(11):1169-86. Doi: 10.2217/imt.15.78Assal A., Kaner J., Pendurti G., Zang X. Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy. 2015;7(11):1169-86. Doi: 10.2217/imt.15.78Sangro B., Gomez-Martin C., de la Mata M., Iñarrairaegui M., Garralda E., Barrera P., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81-88. Doi: 10.1016/j.jhep.2013.02.022.Sangro B., Gomez-Martin C., de la Mata M., Iñarrairaegui M., Garralda E., Barrera P., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81-88. Doi: 10.1016/j.jhep.2013.02.022.Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545-551.Doi: 10.1016/j.jhep.2016.10.029.Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545-551.Doi: 10.1016/j.jhep.2016.10.029.El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T. S., Kudo M., Hsu C., et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502. Doi: 10.1016/S0140-6736(17)31046-2.El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T. S., Kudo M., Hsu C., et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502. Doi: 10.1016/S0140-6736(17)31046-2.Finn R.S., Ryoo B. Y., Merle P., Kudo M., Bouattour M., Lim H. Y., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193-202. Doi: 10.1200/JCO.19.01307.Finn R.S., Ryoo B. Y., Merle P., Kudo M., Bouattour M., Lim H. Y., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193-202. Doi: 10.1200/JCO.19.01307.Yau T., Park J. W., Finn R. S., Cheng A-L., Mathurin P., Edeline J. et al. LBA38_PRCheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(suppl_5): v851-934. Doi: 10.1093/annonc/mdz394.029Yau T., Park J. W., Finn R. S., Cheng A-L., Mathurin P., Edeline J. et al. LBA38_PRCheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(suppl_5): v851-934. Doi: 10.1093/annonc/mdz394.029Zhu W., Peng Y., Wang L., Hong Y., Jiang X., et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology. 2018; 68(2):574-89. Doi: 10.1002/hep.29844.Zhu W., Peng Y., Wang L., Hong Y., Jiang X., et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology. 2018; 68(2):574-89. Doi: 10.1002/hep.29844.Palmer D.H., Midgley R. S., Mirza N., Torr E. E., Ahmed F., Steele J. C. et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009;49(1):124-32. Doi: 10.1002/hep.22626.Palmer D.H., Midgley R. S., Mirza N., Torr E. E., Ahmed F., Steele J. C. et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009;49(1):124-32. Doi: 10.1002/hep.22626.Sawada Y., Yoshikawa T., Ofuji K., Yoshimura M., Tsuchiya N., Takahashi M. et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016; 5(5): e1129483. Doi: 10.1080/2162402X.2015.1129483.Sawada Y., Yoshikawa T., Ofuji K., Yoshimura M., Tsuchiya N., Takahashi M. et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016; 5(5): e1129483. Doi: 10.1080/2162402X.2015.1129483.Shen J., Wang L. F., Zou Z. Y., Kong W. W., Yan J., Meng F. Y. et al. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2017;23(29):5395-5404. Doi: 10.3748/wjg.v23.i29.5395Shen J., Wang L. F., Zou Z. Y., Kong W. W., Yan J., Meng F. Y. et al. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2017;23(29):5395-5404. Doi: 10.3748/wjg.v23.i29.5395Zhou H., Luo Y., Zhu S., Wang X., Zhao Y., Ou X., Zhang T., Ma X. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: a meta-analysis. BMC Cancer. 2018;18(1):929. Doi: 10.1186/s12885-018-4817-4.Zhou H., Luo Y., Zhu S., Wang X., Zhao Y., Ou X., Zhang T., Ma X. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: a meta-analysis. BMC Cancer. 2018;18(1):929. Doi: 10.1186/s12885-018-4817-4.Zhang T., Lu Y., Zeng Z., Yuan J., Chen Y., Xiang J., Liu Z. Phase I dose escalating trail of GPC3-targeted CAR-T cells by intratumor injection for Advanced Hepatocellular carcinoma. Cytotherapy. 2019; 21(5): S10. Doi: 10.1016/j.jcyt.2019.03.566Zhang T., Lu Y., Zeng Z., Yuan J., Chen Y., Xiang J., Liu Z. Phase I dose escalating trail of GPC3-targeted CAR-T cells by intratumor injection for Advanced Hepatocellular carcinoma. Cytotherapy. 2019; 21(5): S10. Doi: 10.1016/j.jcyt.2019.03.566Bonifant C.L., Jackson H. J., Brentjens R. J., Curran K. J. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. Doi: 10.1038/mto.2016.11.Bonifant C.L., Jackson H. J., Brentjens R. J., Curran K. J. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. Doi: 10.1038/mto.2016.11.Moon E.K., Carpenito C., Sun J., Wang L-C.S., Kapoor V., et al. Expression of a functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719-4730. Doi: 10.1158/1078-0432.CCR-11-0351Moon E.K., Carpenito C., Sun J., Wang L-C.S., Kapoor V., et al. Expression of a functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719-4730. Doi: 10.1158/1078-0432.CCR-11-0351Katz S.C., Burga R. A., McCormack E., Wang L. J., Mooring J. W., et al. Phase I Hepatic Immunotherapy for Metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21(14):3149-3159. Doi: 10.1158/1078-0432.CCR-14-1421Katz S.C., Burga R. A., McCormack E., Wang L. J., Mooring J. W., et al. Phase I Hepatic Immunotherapy for Metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21(14):3149-3159. Doi: 10.1158/1078-0432.CCR-14-1421Lin M., Liang S., Wang X., Liang Y., Zhang M., Chen J., Niu L., Xu K. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget. 2017;8(47):81967-77. Doi: 10.18632/oncotarget.17804.Lin M., Liang S., Wang X., Liang Y., Zhang M., Chen J., Niu L., Xu K. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget. 2017;8(47):81967-77. Doi: 10.18632/oncotarget.17804.Romanski A., Uherek C., Bug G., Seifried E., Klingemann H., Wels W. S., Ottmann O. G., Tonn T. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20(7):1287-94. Doi: 10.1111/jcmm.12810.Romanski A., Uherek C., Bug G., Seifried E., Klingemann H., Wels W. S., Ottmann O. G., Tonn T. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20(7):1287-94. Doi: 10.1111/jcmm.12810.Wang W., Jiang J., Wu C. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Cancer Letters. 2020; 472:175-180. Doi: 10.1016/j.canlet.2019.11.033Wang W., Jiang J., Wu C. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Cancer Letters. 2020; 472:175-180. Doi: 10.1016/j.canlet.2019.11.033

The authors declare that there are no conflicts of interest present.